AstraZeneca: Review shows no evidence of increased blood clot risk

Rebecca Falconer
·1 min read

AstraZeneca announced Sunday that safety data review of over 17 million people who've received its COVID-19 vaccine in Europe shows "no evidence" of an increased risk of blood clots.

Stay on top of the latest market trends and economic insights with Axios Markets. Subscribe for free

Why it maters: Authorities in Ireland, the Netherlands, Denmark, Norway and Iceland have paused administering the Oxford-AstraZeneca vaccine amid clotting concerns. Austria suspended its AstraZeneca rollout while authorities investigated the death of one person who had received a dose, per Reuters.

Editor's note: This a breaking news story. Please check back for updates.

More from Axios: Sign up to get the latest market trends with Axios Markets. Subscribe for free